208 related articles for article (PubMed ID: 19303394)
1. Bone morphogenetic protein-7 and Gremlin: New emerging therapeutic targets for diabetic nephropathy.
Zhang Y; Zhang Q
Biochem Biophys Res Commun; 2009 May; 383(1):1-3. PubMed ID: 19303394
[TBL] [Abstract][Full Text] [Related]
2. In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7.
Zhang Q; Shi Y; Wada J; Malakauskas SM; Liu M; Ren Y; Du C; Duan H; Li Y; Li Y; Zhang Y
PLoS One; 2010 Jul; 5(7):e11709. PubMed ID: 20661431
[TBL] [Abstract][Full Text] [Related]
3. Decrease of bone morphogenetic protein-7 (BMP-7) and its type II receptor (BMP-RII) in kidney of type 1-like diabetic rats.
Yeh CH; Chang CK; Cheng MF; Lin HJ; Cheng JT
Horm Metab Res; 2009 Aug; 41(8):605-11. PubMed ID: 19440953
[TBL] [Abstract][Full Text] [Related]
4. Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis.
Mezzano S; Droguett A; Burgos ME; Aros C; Ardiles L; Flores C; Carpio D; Carvajal G; Ruiz-Ortega M; Egido J
Nephrol Dial Transplant; 2007 Jul; 22(7):1882-90. PubMed ID: 17403698
[TBL] [Abstract][Full Text] [Related]
5. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
Sugimoto H; Grahovac G; Zeisberg M; Kalluri R
Diabetes; 2007 Jul; 56(7):1825-33. PubMed ID: 17456853
[TBL] [Abstract][Full Text] [Related]
6. Expression of gremlin, a bone morphogenetic protein antagonist,is associated with vascular calcification in uraemia.
Jara A; Chacón C; Burgos ME; Droguett A; Valdivieso A; Ortiz M; Troncoso P; Mezzano S
Nephrol Dial Transplant; 2009 Apr; 24(4):1121-9. PubMed ID: 19028757
[TBL] [Abstract][Full Text] [Related]
7. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy.
Walsh DW; Roxburgh SA; McGettigan P; Berthier CC; Higgins DG; Kretzler M; Cohen CD; Mezzano S; Brazil DP; Martin F
Biochim Biophys Acta; 2008 Jan; 1782(1):10-21. PubMed ID: 17980714
[TBL] [Abstract][Full Text] [Related]
8. Antagonists of bone morphogenetic proteins in kidney disease.
Yanagita M
Curr Opin Investig Drugs; 2010 Mar; 11(3):315-22. PubMed ID: 20178045
[TBL] [Abstract][Full Text] [Related]
9. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes aristolochic acid-induced epithelial-to-mesenchymal transition (EMT) in HK-2 cells.
Li Y; Wang Z; Wang S; Zhao J; Zhang J; Huang Y
Toxicology; 2012 Jul; 297(1-3):68-75. PubMed ID: 22525892
[TBL] [Abstract][Full Text] [Related]
10. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy.
Dolan V; Murphy M; Sadlier D; Lappin D; Doran P; Godson C; Martin F; O'Meara Y; Schmid H; Henger A; Kretzler M; Droguett A; Mezzano S; Brady HR
Am J Kidney Dis; 2005 Jun; 45(6):1034-9. PubMed ID: 15957132
[TBL] [Abstract][Full Text] [Related]
11. Role of growth factors in diabetic kidney disease.
Chiarelli F; Gaspari S; Marcovecchio ML
Horm Metab Res; 2009 Aug; 41(8):585-93. PubMed ID: 19452424
[TBL] [Abstract][Full Text] [Related]
12. [Relation between bone matrix proteins and monocyte chemoattractant protein-1 in renal small artery in diabetic nephropathy rats].
Zhao AJ; Huang SM; Ou ST; Liu F; Chen ZJ; Hu ZX; Tang WX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 May; 43(3):414-9. PubMed ID: 22812249
[TBL] [Abstract][Full Text] [Related]
13. [Potential therapeutic targets for diabetic nephropathy].
Makino Y; Haneda M
Nihon Rinsho; 2009 Aug; 67(8):1627-35. PubMed ID: 19768953
[TBL] [Abstract][Full Text] [Related]
14. Gremlin: an example of the re-emergence of developmental programmes in diabetic nephropathy.
Lappin DW; McMahon R; Murphy M; Brady HR
Nephrol Dial Transplant; 2002; 17 Suppl 9():65-7. PubMed ID: 12386293
[TBL] [Abstract][Full Text] [Related]
15. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy.
Wang SN; Lapage J; Hirschberg R
J Am Soc Nephrol; 2001 Nov; 12(11):2392-2399. PubMed ID: 11675415
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.
Budhiraja S; Singh J
Fundam Clin Pharmacol; 2008 Jun; 22(3):231-40. PubMed ID: 18485142
[TBL] [Abstract][Full Text] [Related]
17. Gremlin1 preferentially binds to bone morphogenetic protein-2 (BMP-2) and BMP-4 over BMP-7.
Church RH; Krishnakumar A; Urbanek A; Geschwindner S; Meneely J; Bianchi A; Basta B; Monaghan S; Elliot C; Strömstedt M; Ferguson N; Martin F; Brazil DP
Biochem J; 2015 Feb; 466(1):55-68. PubMed ID: 25378054
[TBL] [Abstract][Full Text] [Related]
18. The binding of the bone morphogenetic protein antagonist gremlin to kidney heparan sulfate: Such binding is not essential for BMP antagonism.
Tatsinkam AJ; Rune N; Smith J; Norman JT; Mulloy B; Rider CC
Int J Biochem Cell Biol; 2017 Feb; 83():39-46. PubMed ID: 27979781
[TBL] [Abstract][Full Text] [Related]
19. Gremlin Regulates Podocyte Apoptosis via Transforming Growth Factor-β (TGF-β) Pathway in Diabetic Nephropathy.
Wang XB; Zhu H; Song W; Su JH
Med Sci Monit; 2018 Jan; 24():183-189. PubMed ID: 29315280
[TBL] [Abstract][Full Text] [Related]
20. Gremlin and renal diseases: ready to jump the fence to clinical utility?
Mezzano S; Droguett A; Lavoz C; Krall P; Egido J; Ruiz-Ortega M
Nephrol Dial Transplant; 2018 May; 33(5):735-741. PubMed ID: 28992340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
